Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SNP specialist DxS raises funds to grow business:

This article was originally published in Clinica

Executive Summary

DxS, the Manchester, UK business that was formed by ex-AstraZeneca managers to commercialise proprietary technology to identify single nucleotide polymorphisms in individuals' DNA, has raised some £1m ($1.8m) in a second round of funding. The financing, which was led by Northern Venture Managers (of Newcastle, Reading and Edinburgh), will help DxS expand its in-house testing service for pharmaceutical companies and clinical research organisations, and also broaden its programme of licensing out the Scorpions technology. Scorpions can help predict how a patient will respond to a drug.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts